Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026
← Back to Research Index
Compare Evaluate Matrix Half-Life
Dossier · № 30 of 110 Updated Nov 17, 2026

Sermorelin

GRF 1-29 · Geref

DISCONTINUED (FDA APPROVAL 1990; US WITHDRAWAL 2008) · GHRH ANALOG

▓ 149 indexed citations across PubMed (122), ClinicalTrials.gov (17), EuropePMC (10).

Citation breakdown by evidence tier

← weaker evidence  ·  stronger evidence →

149 citations across 6 tiers

Tap any tier to jump to that section of the bibliography.

Background

Sermorelin acetate, also known as GHRH (1-29), is a peptide analogue of growth hormone-releasing hormone (GHRH) which is used as a diagnostic agent to assess growth hormone (GH) secretion for the purpose of diagnosing growth hormone deficiency. It is a 29-amino acid polypeptide representing the 1–29 fragment from endogenous human GHRH, thought to be the shortest fully functional fragment of GHRH.

→ Wikipedia

Mechanism of action

Binds GHRH receptor on pituitary somatotrophs for pulsatile GH release

Researched effects

Pulsatile GH/IGF-1 stimulation; sleep quality; anti-aging

Reported efficacy (trial readout)

  • Growth Velocity 8 cm/yr

    JCEM (Phase 3, 26wk, n=86)

    Medium confidencen=86Phase 31996

Trial-efficacy data current as of November 16, 2026.

Live evidence

Live signals refreshed daily. Current as of November 19, 2026.

Dosing reported in literature

200-500 mcg SC at bedtime daily

Known concerns

Injection site reactions; headache; flushing

Top-ranked picks

10 pre-curated authoritative sources, ranked by journal tier and study weight.

  1. Investigation of a New, Oral Growth Hormone Secretagogue, AEZS-130 as a Growth Hormone Stimulation Test.

    2007 — TRIAL REGISTRATIONS (CLINICALTRIALS.GOV) · AUTHORITY 73.7

  2. Comparative Validation of the Growth Hormone Releasing Hormone and Arginine Test for the Diagnosis of Adult Growth Hormone Deficiency

    2004 — TRIAL REGISTRATIONS (CLINICALTRIALS.GOV) · AUTHORITY 73.4

  3. Aspartate and glutamate modulation of growth hormone secretion in the pig: possible site of action.

    Domestic animal endocrinology · 1996 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 72.0

  4. Effect of galanin on the growth hormone (GH) response to GH-releasing hormone in patients with Cushing's disease.

    Endocrine research · 1993 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 72.0

  5. Lack of effect of muscarinic cholinergic blockade on the GH responses to GRF 1-29 and TRH in acromegalic subjects.

    Clinical endocrinology · 1986 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 72.0

  6. Influence of dopaminergic, adrenergic and cholinergic blockade and TRH administration on GH responses to GRF 1-29.

    Clinical endocrinology · 1986 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 72.0

  7. Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese

    2008 — TRIAL REGISTRATIONS (CLINICALTRIALS.GOV) · AUTHORITY 71.8

  8. Adult Growth Hormone Deficiency and Cardiovascular Risk

    2007 — TRIAL REGISTRATIONS (CLINICALTRIALS.GOV) · AUTHORITY 71.7

  9. The Effect of GHRH Therapy on Myocardial Structure and Function in Congestive Heart Failure

    2004 — TRIAL REGISTRATIONS (CLINICALTRIALS.GOV) · AUTHORITY 71.4

  10. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.

    The Journal of clinical endocrinology and metabolism · 1996 — CLINICAL TRIALS · AUTHORITY 71.0

Full citation library

Year distribution

Randomised Controlled Trials

4
  1. 1.

    Jordan V, Dieguez C, Valcavi R, Artioli C, et al. · Clinical endocrinology · 1986 · PMID 2874906

    It is well known that muscarinic cholinergic blockade either reduces or abolishes stimulated GH release in normal subjects. In this study we have investigated whether cholinergic muscarinic blockade could reduce the GH responses to GRF 1-29 and TRH in acromegalic subjects. Eight acromegalic subjects underwent two GRF tests (GRF 1-29, 1 microgram/kg i.v.) with and without pirenzepine (0.6 mg/kg, i.v.). A further four of these patients received TRH (200 micrograms/kg, i.v.) on separate occasions w…

  2. 2.

    Giustina A, Bossoni S, Bussi AR, Pozzi A, et al. · Endocrine research · 1993 · PMID 7681769

    Attenuated plasma GH secretion during sleep and blunted GH responses to provocative stimuli have been observed in patients with Cushing's disease. Synthetic porcine galanin elicits GH secretion when given alone, and enhances the GH response to GHRH in normal human subjects. The aim of our study was to investigate the effects of galanin on the GH response to GHRH in patients with Cushing's disease. We studied 5 female subjects with untreated active Cushing's disease caused by micro-pituitary aden…

  3. 3.

    Jordan V, Dieguez C, Lafaffian I, Rodriguez-Arnao MD, et al. · Clinical endocrinology · 1986 · PMID 2871952

    In order to establish the influence of dopaminergic, alpha-adrenergic and cholinergic pathways on GRF-mediated GH release we have studied the GH responses to GRF 1-29 (100 or 50 micrograms as i.v. bolus) alone and in combination with metoclopramide (MCP, 10 mg, i.v.), thymoxamine (THYM, 210 micrograms/min, 150 min infusion), and atropine (1.2 mg, i.v.). We have also investigated any possible interaction between TRH and GRF in view of the reported inhibitory effects of TRH infusion on stimulated…

  4. 4.

    Barb CR, Campbell RM, Armstrong JD, Cox NM · Domestic animal endocrinology · 1996 · PMID 8625618

    The influence of excitatory amino acids (EAA) on growth hormone (GH) secretion and the possible site of action was investigated in the pig. In Experiment (Exp) I three replicates were conducted with 30 prepuberal gilts, 130 d of age and averaging 70.6 +/- 1.3 kg body weight (BW). Six gilts each received intravenously (i.v.) 0, 50, 100, or 150 mg/kg BW of aspartate (ASP) or glutamate (GLU) in saline. Blood samples were collected every 15 min for 2 hr before and 3 hr after treatment. In Exp II, ma…

Clinical Trials

7
  1. 5.

    Thorner M, Rochiccioli P, Colle M, Lanes R, et al. · The Journal of clinical endocrinology and metabolism · 1996 · PMID 8772599

    The efficacy and safety of 1 yr of GH-releasing hormone [GHRH-(1-29)] therapy in GH-deficient children were determined. One hundred and ten previously untreated prepubertal GH-deficient children were treated for up to 1 yr in a multicenter, open label study with 30 micrograms/kg GHRH-(1-29)/day, sc, given at bedtime. Eighty-six of the 110 patients were eligible for efficacy analysis. The main outcome measures, monitored every 3-6 months, were linear growth enhancement (height velocity), bone age…

  2. 6.

    Saenger P, Pescovitz OH, Bercu BB, Murray FT, et al. · Endocrine · 2001 · PMID 11572326

    Saizen (recombinant growth hormone [GH]), 0.2 mg/(kg x wk), was given in an open-label fashion for an average of 51 mo to 27 children with presumed idiopathic GH deficiency who had withdrawn from a trial of Geref (recombinant GH-releasing hormone [GHRH] 1-29) because of inadequate height velocity (HV) (25 children), the onset of puberty (1 child), or injection site reactions (1 child). Measurements were made every 3-12 mo of a number of auxologic variables, including HV, height standard deviatio…

  3. 7.

    Bellone J, Bellone S, Aimaretti G, Valetto MR, et al. · Journal of endocrinological investigation · 2000 · PMID 10803472

    Aim of the present study was to further clarify the negative GH auto-feedback mechanisms in childhood. To this goal we studied the effects of rhGH and/or GHRH administration on the GH response to GHRH or hexarelin (HEX), a peptidyl GH secretagogue, in normal short children. In 34 prepubertal children (12 girls and 22 boys, age 8.2- 14.2 yr) with normal short stature (normal height velocity and IGF-I levels) the following tests were performed: group A (no.=11): GHRH (GHRH 1 - 29, Geref, Serono; 1…

  4. 8.

    Alvarez XA, Cacabelos R · Methods and findings in experimental and clinical pharmacology · 1990 · PMID 2087150

    Recent studies seem to indicate that the somatotropinergic system (STS) (GRF-SS-GH-SM axis) may be involved in the neuromodulation of higher activities of the central nervous system (CNS). In an attempt to demonstrate the influence of the STS on memory functions in humans, we have investigated the effects of acute administration of exogenous GRF vs. placebo on short-term memory (STM) in healthy young subjects. We gave GRF(1-29)NH2 (150 micrograms; i.v.) to a group of subjects (EG) (N = 17) and p…

  5. 9.

    Lima L, Arce V, Diaz MJ, Tresguerres JA, et al. · The Journal of clinical endocrinology and metabolism · 1993 · PMID 8094392

    The aim of this study was to investigate the mechanisms by which glucocorticoids inhibit GH secretion in man. In 10 normal volunteers subjects we compared the pattern of GHRH-induced GH release to that elicited by similar challenge given 60 min after a pretreatment with drugs affecting adrenergic and muscarinic cholinergic neurotransmission, both in basal situations and after having induced hypercortisolism. In a first study (P), synthetic GHRH [GRF-(1-29); 1 microgram/kg, i.v.] was administered…

  6. 10.

    Devesa J, Diaz MJ, Tresguerres JA, Arce V, et al. · The Journal of clinical endocrinology and metabolism · 1991 · PMID 1677361

    The aim of this study was to investigate the interrelationships between alpha 2-adrenergic and cholinergic pathways in the control of hypothalamic somatostatin (SRIF) secretion in humans. In eight normal volunteers subjects we compared the pattern of GHRH-induced GH release to that elicited by similar challenge given 60 min after a pretreatment with drugs affecting alpha 2-adrenergic and muscarinic cholinergic neurotransmission. In a control study, synthetic GHRH [GRF-(1-29); 1 microgram/kg, iv]…

  7. 11.

    Devesa J, Arce V, Lois N, Tresguerres JA, et al. · The Journal of clinical endocrinology and metabolism · 1990 · PMID 1977761

    The purpose of this study was to investigate the precise mechanism by which central alpha 2-adrenergic pathways modulate GH secretion in humans. In 10 normal subjects we compared the pattern of clonidine-induced GH release to that elicited by GH-releasing hormone (GHRH) given at a time of presumably similar responsiveness of the somatotrope. We also evaluated the effect of stimulation by GHRH (either endogenous, by administration of clonidine, or exogenous) on the GH response to a further exogen…

Trial Registrations (ClinicalTrials.gov)

17
  1. 12.

    NCT00720902 · Phase 4 · Terminated · 2007

    Conditions: Growth Hormone Deficiency

  2. 13.

    NCT02271282 · Phase 1 · Completed · 2014

    Conditions: Normal Healthy Volunteers

  3. 14.

    NCT02507245 · Completed · 2014

    Conditions: Growth Hormone Deficiency

  4. 15.

    NCT00448747 · Phase 3 · Completed · 2007

    Conditions: Diagnosis of Adult Growth Hormone Deficiency (AGDH)

  5. 16.

    NCT00791843 · Phase 2 · Completed · 2004

    Conditions: Congestive Heart Failure

  6. 17.

    NCT02736591 · Phase 3 · Unknown · 2016

    Conditions: Subfertility

  7. 18.

    NCT00795210 · NA · Completed · 2009

    Conditions: HIV Lipodystrophy

  8. 19.

    NCT00324064 · NA · Completed · 2007

    Conditions: Growth Hormone Deficiency

  9. 20.

    NCT01263717 · NA · Completed · 2010

    Conditions: HIV, HIV Lipodystrophy

  10. 21.

    NCT00807365 · Phase 2 · Terminated · 2007

    Conditions: Elderly

  11. 22.

    NCT00675506 · Phase 2 · Completed · 2008

    Conditions: Abdominal Obesity, Growth Hormone Deficiency

  12. 23.

    NCT02553603 · Phase 1 · Completed · 2017

    Conditions: Mild Cognitive Impairment

  13. 24.

    NCT01410799 · Phase 2 · Terminated · 2011

    Conditions: Hormone Deficiency, Aging

  14. 25.

    NCT00000380 · NA · Completed · 1996

    Conditions: Sleep Disorders

  15. 26.

    NCT00850564 · NA · Completed · 2009

    Conditions: Healthy Volunteers

  16. 27.

    NCT02931474 · Phase 2 · Withdrawn · 2016

    Conditions: Sleep Disorder, Traumatic Brain Injury

  17. 28.

    NCT01060488 · Phase 3 · Completed · 2004

    Conditions: Growth Hormone Deficiency

Reviews

5
  1. 29.

    Rahman OF, Lee SJ, Seeds WA · Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2026 · PMID 41490200

    Therapeutic peptides are emerging as promising adjuncts in the management of orthopaedic injuries, grounded in their ability to modulate molecular signaling networks central to cellular medicine. By acting on key pathways such as PI3K/Akt, mTOR, MAPK, TGF-β, and AMPK, peptides exert influence over tissue regeneration, inflammation resolution, and neuromuscular recovery. Wound-healing peptides such as BPC-157, TB-500, and GHK-Cu promote angiogenesis, integrin-mediated extracellular matrix remodel…

  2. 30.

    Sinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, et al. · Translational andrology and urology · 2020 · PMID 32257855

    Male hypogonadism is an increasingly prevalent clinical condition that affects patients' quality of life and overall health. Obesity and metabolic syndrome can both cause and result from hypogonadism. Although testosterone remains the gold standard for hypogonadism management, its benefits are not always conserved across different populations, especially with regards to changes in body composition. Partially in response to this, growth hormone secretagogues (GHS) have emerged as a potential nove…

  3. 31.

    Esposito P, Barbero L, Caccia P, Caliceti P, et al. · Advanced drug delivery reviews · 2003 · PMID 14499707

    Synthetically produced GRF1-29 (Sermorelin) has an amino acid composition identical to the N-terminal 29 amino acids sequence of the natural hypothalamic GHRH1-44 (Figure 1). It maintains bioactivity in vitro and is almost equally effective in eliciting secretion of endogenous growth hormone in vivo. The main drawbacks associated with the pharmaceutical use of hGRF1-29 relate to its short half-life in plasma, about 10-20 min in humans, which is caused mostly by renal ultrafiltration and enzymati…

  4. 32.

    Mendias CL, Awan TM · Sports medicine (Auckland, N.Z.) · 2026 · PMID 41966639

    Peptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins. Their use in sports medicine is rapidly expanding, driven by patient demand for accelerated injury recovery and performance enhancement. While numerous peptide drugs have undergone a rigorous approval process that evaluates both safety and efficacy, a parallel "gray market" of unapproved compounds has emerged, operating largely outside of regulatory oversight. Our objecti…

  5. 33.

    Yuen KC, Biller BM, Molitch ME, Cook DM · The Journal of clinical endocrinology and metabolism · 2009 · PMID 19509104

    The use of the combined GHRH and arginine (GHRH-ARG) test has gained increasing acceptance in the United States as a reliable alternative test to the insulin tolerance test (ITT) for diagnosing adult GH deficiency (GHD). In July 2008, the only manufacturer of recombinant GHRH in the United States, EMD Serono, Inc., announced the discontinuation of Geref, thus raising the question of which reliable alternative GH stimulation test should practicing endocrinologists be considering in place of the G…

Research Articles

113
  1. 34.

    Memdouh S, Gavrilović I, Ng K, Cowan D, et al. · Drug testing and analysis · 2021 · PMID 34665524

    The administration of growth hormone releasing hormone (GHRH) and its synthetic analogs is prohibited by the World Anti-Doping Agency (WADA). Although there is evidence of their use, based on admissions and intelligence, they do not appear to have been found in anti-doping samples by WADA accredited laboratories. This might be due to their small concentration in urine and limited knowledge about their metabolism, especially for unapproved synthetic analogs. This study investigates the in vitro m…

  2. 35.

    Cristea CD, Radu M, Toboc A, Stan C, et al. · Analytical biochemistry · 2023 · PMID 37806509

    The use of growth hormone-releasing hormones (GHRHs) is prohibited in sports according to the regulations of the World Anti-Doping Agency (WADA). Considering the complexity of urine samples and the low concentrations at which these analytes should be detected, analyzing GHRHs is a challenging task. In most of the studies, GHRHs are analyzed using UHPLC-HRMS with an orbitrap. The present developed and validated method for some GHRHs (tesamorelin, CJC-1295, sermorelin (GRF 1-29), sermorelin (3-29)…

  3. 36.

    González-López NM, Guerra-Acero-Turizo LM, Blanco-Medina I, Barragán-Cárdenas AC, et al. · Biomedical chromatography : BMC · 2023 · PMID 37688464

    Matrix effect and sample pretreatment significantly affect the percentage recovery of peptides in biological matrices, affecting the method robustness and accuracy. To counteract this effect, an internal standard (IS) is used; however, in most cases this is not available, which limits the analytical method. It is important to identify short peptides that can be used as ISs in the quantification of peptides in biological matrices. In this study, doping peptides GHRP-4, GHRP-5, GHRP-6, Sermorelin…

  4. 37.

    Otin J, Tran NT, Benoit A, Buisson C, et al. · Electrophoresis · 2023 · PMID 36787346

    A capillary electrophoresis method is proposed to analyze the four most well-known growth hormone-releasing hormone (GHRH) analogs that are misused by athletes. Dimethyl-β-cyclodextrin used as a chiral selector allowed, for the first time, the separation of those basic peptide analogs, including enantiopeptides (sermorelin and CJC-1293) that differ by the chirality of only one amino acid. To increase the method sensitivity, electrokinetic preconcentration methods have been investigated. The larg…

  5. 38.

    Popovic V, Pekic S, Golubicic I, Doknic M, et al. · The Journal of clinical endocrinology and metabolism · 2002 · PMID 11994347

    Patients treated with cranial radiation are at risk of GH deficiency (GHD). We evaluated somatotroph responsiveness to maximal provocative tests exploring the GH releasable pool in relation to the impact of radiation damage to the hypothalamic-pituitary unit. The GH-releasing effect of GHRH plus GH secretagogue [GH-releasing peptide (GHRP)-6] (GHRH+GHRP-6) was studied in 22 adult patients (age, 23.2 +/- 1.4 yr; 8 female and 14 male; mean body mass index, 22.6 +/- 0.7 kg/m(2)) who received crania…

  6. 39.

    Knoop A, Thomas A, Fichant E, Delahaut P, et al. · Analytical and bioanalytical chemistry · 2016 · PMID 26879649

    The use of growth hormone-releasing hormones (GHRHs) is prohibited in sports according to the regulations of the World Anti-Doping Agency (WADA). The aim of the present study was to develop a method for the simultaneous detection of four different GHRHs and respective metabolites from human plasma by means of immunoaffinity purification and subsequent nano-ultrahigh performance liquid chromatography-high resolution/high accuracy (tandem) mass spectrometry. The target analytes included Geref (Ser…

  7. 40.

    Walker RF · Clinical interventions in aging · 2006 · PMID 18046908

  8. 41.

    Coppieters G, Deventer K, Polet M, Van Eenoo P, et al. · Journal of pharmaceutical and biomedical analysis · 2022 · PMID 35298973

    This work presents an ultrafiltration-based, validated method for the screening and confirmation of prohibited growth hormone-releasing hormone (GHRH) analogues (sermorelin/CJC-1293, sermorelin metabolite, CJC-1295 and tesamorelin) in urine by nanoLC-HRMS/MS. Sample preparation avoids the use of laborious antibody-based extraction approaches and consists solely of preconcentration by ultrafiltration. Even in the absence of immuno-affinity purification steps, high sensitivity was still ensured as…

  9. 42.

    Prakash A, Goa KL · BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 1999 · PMID 18031173

    Sermorelin, a 29 amino acid analogue of human growth hormone-releasing hormone (GHRH), is the shortest synthetic peptide with full biological activity of GHRH. Intravenous and subcutaneous sermorelin specifically stimulate growth hormone secretion from the anterior pituitary. Hormone responses to intravenous sermorelin 1 microg/kg bodyweight appear to be a rapid and relatively specific test for the diagnosis of growth hormone deficiency. False positive growth hormone responses are observed in fe…

  10. 43.

    Chang Y, Huang R, Zhai Y, Huang L, et al. · Annals of translational medicine · 2021 · PMID 33842627

    Treatment insensitivity is the main cause of glioma. This study was designed to screen out effective drugs for recurrent gliomas based on the transcriptomics data. A total of 1,018 glioma patients with transcriptome sequencing data and clinical data were included in this study. There were 325 patients in the discovery cohort, including 229 primary patients and 92 recurrent patients. There were 693 patients in the validation cohort, including 422 primary patients and 271 relapsed patients. Drug R…

  11. 44.

    Ramirez G, Herrera R, Pineda D, Bittle PA, et al. · Clinical endocrinology · 1995 · PMID 7641401

    Individuals adapted to high altitude (HA) have abnormalities in endocrine function and specifically in the pituitary-thyroid axis and aldosterone regulation. In this study we assessed hypothalamic-pituitary function in men adapted to high altitude living using exogenous administration of synthetic hypothalamic hormones. Growth hormone releasing hormone (Geref 1-29) 1 microgram/kg, TRH 500 micrograms, GHRH 100 micrograms and ovine corticotrophin releasing hormone (oCRH) 1 microgram/kg were simult…

  12. 45.

    Robberecht P, Coy DH, Waelbroeck M, Heiman ML, et al. · Endocrinology · 1985 · PMID 2994998

    The efficacy and potency of 14 GH-releasing factor (GRF) analogs, substituted in position 1 to 7, on adenylate cyclase activation in crude homogenates from rat anterior pituitary were related to those of human pancreatic GRF(1-29)-amide and vasoactive intestinal peptide. Among several D-amino acid substitutions, that in position 2 was the only one to yield a super-agonist [with a Kact (concentration required for half-maximal adenylate cyclase activation) 2 times lower than that of GRF(1-29)-NH2]…

  13. 46.

    de Zegher F, Vanderschueren-Lodeweyckx M, Spitz B, Faijerson Y, et al. · The Journal of clinical endocrinology and metabolism · 1990 · PMID 2143200

    To study regulation of the secretion of human pituitary GH (hGH) and placental GH (hPGH) in the pregnant woman and human fetus, the GH-releasing factor Sermorelin [GRF-(1-29)-NH2] was administered to pregnant women at term (n = 5), just before elective cesarean section; saline was administered in control studies (n = 5). The effects of GRF-(1-29)-NH2 administration on maternal and fetal serum concentrations of hGH and GRF-(1-29)-NH2 and maternal serum levels of hPGH were evaluated at birth. The…

  14. 47.

    Gajda PM, Holm NB, Hoej LJ, Rasmussen BS, et al. · Drug testing and analysis · 2019 · PMID 30136411

    A number of unknown pharmaceutical preparations seized by Danish customs authorities were submitted for liquid chromatography-high resolution mass spectrometry (LC-HRMS) analysis. Comparison with reference standards unequivocally identified the content of the powders as analogs of the growth hormone secretagogues GHRP-2 (Pralmorelin), GHRP-6, Ipamorelin, and modified growth hormone releasing factor (modified GRF 1-29), which can be used as performance-enhancing substances in sports. In all cases…

  15. 48.

    Waelbroeck M, Robberecht P, Coy DH, Camus JC, et al. · Endocrinology · 1985 · PMID 2859987

    Adenylate cyclase stimulation by GH-releasing factor (GRF) and 14 GRF analogs (modified in the N-terminal part) was compared to the capacity of the same peptides to inhibit [125I]iodo-vasoactive intestinal peptide (VIP) binding in rat pancreatic plasma membranes. These peptides interfered with VIP receptors as they inhibited [125I]iodo-VIP binding, and probably acted through VIP-preferring receptors as one of these peptides [(N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2] selectively inhibited both VIP- and G…

  16. 49.

    Mariette B, Coudane J, Vert M · Journal of controlled release : official journal of the Controlled Release Society · 2005 · PMID 15987661

    The administration of the GRF(1-29)NH2 Growth Hormone Releasing Hormone analog is known as relevant of the concept of drug delivery system using a bioresorbable matrix. However, the release of this peptide from poly(dl-lactic acid-co-glycolic acid) matrices is affected by its insolubility at neutral in salted media and in plasma as well. In order to investigate the origin and the nature of the insolubility in these media in more details, the precipitates collected when the peptide was set in con…

  17. 50.

    Bai JP, Chang LL · The Journal of pharmacy and pharmacology · 1995 · PMID 8583376

    GRF(1-29)NH2 is degraded mainly by dipeptidyl peptidase IV (DPP IV) in plasma, resulting in inactivated GRF(3-29)NH2. To understand whether improving stability of GRF(1-29)NH2 in the plasma will result in enhanced stability in intestinal mucosal cells, stability of GRF(1-29)NH2 and [desNH2Tyr1,D-Ala2,Ala15]-GRF(1-29)NH2 in rat intestine brush-border membrane and homogenate was examined. [desNH2Tyr1,D-Ala2,Ala15]-GRF(1-29)NH2, resistant to plasma DPP IV, was much more stable than GRF(1-29)NH2 in…

  18. 51.

    Pasqualini T, Ferraris J, Fainstein-Day P, Eymann AA, et al. · Medicina · 1996 · PMID 9035479

    Growth retardation is a prominent clinical manifestation in children with chronic renal failure (CRF). Nine children with CRF (3 on conservative treatment; 3 on dialysis and 3 after renal transplantation) aged 1.6 to 14.0 (x +/- SE: 8.1 +/- 1.4) years, were treated with twice daily subcutaneous injections of 26 +/- 2.4 micrograms/kg/day growth-hormone-releasing-hormone [GHRH (1-29) NH2 Serono (Geref)] during 3 to 6 months. Mean serum urea and creatinine remained stable, although 2 patients on co…

  19. 52.

    Ranke MB, Gruhler M, Rosskamp R, Brügmann G, et al. · European journal of pediatrics · 1986 · PMID 2880720

    Growth hormone (GH) responses to GRF (1 microgram/kg BW i.v.) were investigated. Comparison between GRF(1-40) and GRF(1-29)NH2 in 11 young adult volunteers gave identical results. One hundred and thirty-one children and adolescents (45 with idiopathic GHD) were tested with GRF (1-29)NH2. The maximal GH levels (max GH) in response to GRF during the 120 min test period were found suitable to characterize the response. In cases without GHD no correlation to age, sex and pubertal development was obs…

  20. 53.

    Felix AM, Heimer EP, Wang CT, Lambros TJ, et al. · International journal of peptide and protein research · 1988 · PMID 3149952

    A novel cyclic GRF analog, cyclo(Asp8-Lys12)-[Asp8,Ala15]-GRF(1-29)-NH2, i.e. cyclo8,12[Asp8,Ala15]-GRF(1-29)-NH2, was synthesized by the solid phase procedure and found to retain significant biological activity. Solid phase cyclization of Asp8 to Lys12 proceeded rapidly (approximately 2 h) using the BOP reagent. Substitution of Ala2 with D-Ala2 and/or NH2-terminal replacement (desNH2-Tyr1 or N-MeTyr1) in the cyclo8,12[Asp8,Ala15]-GRF(1-29)-NH2 system resulted in highly potent analogs that were…

  21. 54.

    Kraicer J, French MB, Lussier BT, Moor BC, et al. · Canadian journal of physiology and pharmacology · 1991 · PMID 1829020

    The purpose of this study was to characterize the biological activity of the synthetic rat growth hormone releasing factor analogue rGRF(1-29)NH2 and to compare its action on growth hormone (GH) release to that of authentic rGRF(1-43)OH. We first compared the concentration-response characteristics of the two peptides in static incubation, and then examined the reversibility and repeatability of the GH response in a perifusion system. Authentic rGRF(1-43)OH was significantly more potent in static…

  22. 55.

    D'Antonio M, Louveau I, Esposito P, Bertolino M, et al. · Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2004 · PMID 15125884

    The aim of this study was to assess the in vivo efficacy of monoPEGylated GRF(1-29)NH(2) having one PEG(5000) chains attached to either lysine 12 or 21 as compared to the GRF(1-29)NH(2) in rats and pigs. This analogue termed GRF-1PEG(5000) was tested after a single intravenous administration in rats and after a single intravenous or subcutaneous injection in pigs. After 1 h administration, GH concentrations returned to values close to controls in the group of rats injected with GRF(1-29)NH(2). I…

  23. 56.

    Blank MA, Kimura K, Fuortes M, Jaffe BM · The American journal of physiology · 1990 · PMID 2116730

    The effect of the vasoactive intestinal polypeptide (VIP) antagonist [N-Ac-Tyr1,D-Phe2]-GRF-(1-29)-NH2 on pelvic nerve-induced colonic vasodilation and VIP release was investigated in chloralose-anesthetized cats. VIP antagonist (10 and 50 nmol/kg in saline) or saline alone was injected into a branch of the superior mesenteric artery immediately before bilateral pelvic nerve stimulation. The increase in conductance in the inferior mesenteric artery during pelvic nerve stimulation was reduced in…

  24. 57.

    Youn YS, Lee KC · Bioconjugate chemistry · 2007 · PMID 17243755

    PEGylation has been viewed as an effective means of overcoming the therapeutic restriction of growth hormone-releasing factor (1-29) (GRF(1-29)) due to its short biological lifetime caused by severe proteolysis and rapid glomerular filtration. Of three isomers according to the PEGylation sites (Tyr1, Lys12, or Lys21), PEGylated GRF(1-29) at Lys21-amine (Lys21-PEG-GRF(1-29)) was shown to have the highest bioactivity. In this report, we propose a unique two-step site-specific PEGylation method cap…

  25. 58.

    Davis JR, Sheppard MC, Shakespear RA, Lynch SS, et al. · Clinical endocrinology · 1986 · PMID 2871948

    It is unclear whether growth hormone releasing factor (GRF) administration in vivo may desensitize the somatotroph. To investigate this possibility we have examined the effects of 10-h infusion of the equipotent 1-29 amide analogue of hpGRF on serum GH levels and on the subsequent GH response to a bolus dose of GRF (1-29). Four normal adult males received an intravenous infusion of 1-29 GRF (1 microgram/kg/h) from 0800 to 1800 h, with blood samples taken at 10 min intervals. A 100 micrograms int…

  26. 59.

    Sigalos JT, Pastuszak AW, Allison A, Ohlander SJ, et al. · American journal of men's health · 2017 · PMID 28830317

    Realizing the reported misuse of human growth hormone (GH), investigation of a safe alternative mechanism for increasing endogenous GH is needed. Several GH secretagogues are available, including GH-releasing peptides (GHRPs) GHRP-2 and GHRP-6, and the GH-releasing hormone analog, sermorelin (SERM). Insulin-like growth factor 1 (IGF-1) serves as a surrogate marker for GH. Here, the effect of GHRP/SERM therapy on IGF-1 levels is evaluated. A retrospective review of medical records was performed f…

  27. 60.

    Uçaktürk E, Nemutlu E · Journal of pharmaceutical and biomedical analysis · 2026 · PMID 41138283

    Growth hormone-releasing hormone (GHRH) and its synthetic analogs are considered performance-enhancing substances and are therefore prohibited by the World Anti-Doping Agency (WADA). The analysis of GHRH and its analogs in urine presents significant analytical challenges due to their inherent in vivo instability, rapid renal clearance, and low urinary concentrations. The present study aimed to develop a robust nano-LC quadrupole/orbitrap mass spectrometry (nano-LC-Q/Orbitrap MS) method for both…

  28. 61.

    Aguilar E, López F · Journal of steroid biochemistry · 1988 · PMID 2898557

  29. 62.

    Luo D, McKeown BA · Neuroendocrinology · 1991 · PMID 1684643

    Possible antagonism between somatostatin (SS) and carp growth hormone-releasing factor (GRF) on growth hormone (GH) secretion was examined by radioimmunoassay in a dispersed rainbow trout pituitary cell culture system. SS (3 nM) significantly antagonized carp GRF(1-29; 1 nM, 10 nM)-induced GH secretion. The slope of the dose-response curve for carp GRF(1-29) with SS was statistically different from that of carp GRF(1-29) alone (p less than 0.05) suggesting a noncompetitive antagonism of SS to ca…

  30. 63.

    Pozo D, Montilla ML, Guerrero JM, Calvo JR · European journal of pharmacology · 1997 · PMID 9085051

    In the present study we show that the synthetic peptides [4-Cl-D-Phe6,Leu17]VIP and the growth hormone releasing factor (GRF) analog [Ac-Tyr1,D-Phe2]GRF-(1-29)-NH2 inhibit in a competitive manner the specific [125I]VIP binding to both rat and mouse peritoneal macrophages. In rat peritoneal macrophages, the order of potency of the different peptides, as expressed by the IC50 values was: VIP (IC50 = 1.90 +/- 0.16 nM) > [4-Cl-D-Phe6,Leu17]VIP (IC50 = 125.8 +/- 13.2 nM) > [Ac-Tyr1,D-Phe2]GRF-(1-29)-…

  31. 64.

    Genazzani AD, Petraglia F, Gastaldi M, Gamba O, et al. · Fertility and sterility · 1996 · PMID 8612852

    To evaluate the GH-releasing hormone (GH-RH)-induced response of GH in patients affected by hypothalamic amenorrhea. Patients affected by weight-loss-related hypothalamic amenorrhea (n = 28) were studied and compared with 20 healthy controls. Among patients with weight-loss amenorrhea, both hypogonadotropic and normogonadotropic conditions were present. All subjects underwent a GH-RH test (GEREF, Sereno, Rome, Italy) (1 microgram/kg body weight IV). Plasma GH concentrations were determined using…

  32. 65.

    Borkenstein M · Acta endocrinologica. Supplementum · 1986 · PMID 2877535

    The effects of intranasal insufflation of the synthetic growth hormone releasing factor GRF 1-29-NH2 on serum growth hormone (GH) were investigated in five healthy prepubertal children with short stature. 100 micrograms/kg/body weight of synthetic GRF 1-29-NH2, 500 micrograms in 100 microliters water, were insufflated intranasally after careful cleaning of the nose. GRF 1-29-NH2 induced a prompt rise of serum GH levels with peak values at 15 minutes in all children investigated. Peak serum GH va…

  33. 66.

    Valcavi R, Jordan V, Dieguez C, John R, et al. · Clinical endocrinology · 1986 · PMID 3098458

    It is well known that hypothyroidism is frequently associated with impaired GH responses to different stimuli. In the present study we have evaluated GH responses to GH-releasing factor (GRF) in patients with primary hypothyroidism before and during T4 replacement therapy. Fourteen patients (age range 26-60 years) underwent two GRF tests (1 microgram/kg) before and during replacement therapy (150 micrograms/d). Administration of T4 increased peak GH responses to GRF in 9 patients and in the grou…

  34. 67.

    Coutinho LFD, DE Oliveira Neves LF, Camilo RP · The Journal of sports medicine and physical fitness · 2026 · PMID 41880199

    The pursuit of pharmacological enhancement in sport has evolved from the widespread use of anabolic-androgenic steroids (AAS) to novel agents such as peptides and peptide analogues. Marketed as more selective and ostensibly safer alternatives, peptides-including growth hormone secretagogues (e.g., Ipamorelin), growth hormone-releasing hormone analogues (e.g., CJC-1295, Sermorelin), and synthetic fragments (e.g., Frag 176-191, KPV)-are promoted for muscle growth, fat metabolism, recovery, and ant…

  35. 68.

    Bongers J, Heimer EP, Lambros T, Pan YC, et al. · International journal of peptide and protein research · 1992 · PMID 1428526

    Products of the degradation of human growth hormone-releasing factor (GRF) in aqueous solutions (15-200 microM) have been isolated and fully characterized. The cleavage product, GRF(4-44)-NH2, and the isomerization product, [beta-Asp3]GRF(1-44)-NH2, from the degradation of GRF(1-44)-NH2 in acidic solution and the corresponding products, GRF(4-29)-NH2 and [beta-Asp3]GRF(1-29)-NH2, from the degradation of GRF(1-29)-NH2 have been isolated and characterized. The products, [beta-Asp8]GRF(1-44)-NH2 an…

  36. 69.

    Bongers J, Lambros T, Ahmad M, Heimer EP · Biochimica et biophysica acta · 1992 · PMID 1353684

    The kinetics and selectivity of proteolysis of synthetic human growth hormone-releasing factor and analogs by purified human placental dipeptidyl peptidase IV (DPP IV) were studied by HPLC. The initial rates of Ala2-Asp3 cleavage (pH 7.8, 37 degrees C, So = 0.15 mM) were all approx. 5 mumol min-1 mg-1 for the parent hormone, GRF(1-44)-NH2, and the fragments, GRF(1-29)-NH2 and GRF(1-20)-NH2. Lower activities observed for GRF(1-11)-OH, GRF(1-3)-OH, and cyclic lactam analogs indicate S1'-Sn' bindin…

  37. 70.

    Suzuki S, Kawai K, Ohashi S, Watanabe Y, et al. · Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 1992 · PMID 1464409

    Previous studies have demonstrated that glucagon-superfamily peptides stimulate insulin release from the pancreatic islets in a glucose dependent manner. In this study we have carried out a structure-activity study of their insulinotropic activity using a rat pancreas perfusion with 5.5 mM glucose concentration. The following peptides were examined: glucagon-like peptide-1(7-36)amide (tGLP-1), glucagon, gastric inhibitory peptide (GIP), peptide having an amino-terminal histidine and carboxy-term…

  38. 71.

    Coy DH, Murphy WA, Sueiras-Diaz J, Coy EJ, et al. · Journal of medicinal chemistry · 1985 · PMID 3918170

    In previous reports illustrating the effects of conformational restriction of the N-terminal region of human pancreatic growth hormone releasing factor, we demonstrated that D-amino acid substitutions in either of positions 1, 2, or 3 resulted in greatly increased growth hormone releasing activity both in vivo and in vitro. The most active compound, [D-Ala-2]GRF(1-29)NH2, was 51 times more active than the parent 29 amino acid peptide in the sodium pentobarbital anesthetized rat. These observatio…

  39. 72.

    Estévez MD, Alfonso A, Vieytes MR, Louzao MC, et al. · Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 1995 · PMID 7544679

    Human growth releasing factor (GRF) (1-29)NH2 releases histamine from pleural and peritoneal rat mast cells by a non cytotoxic and non immunological mechanism. Pretreatment of cells with pertussis toxin markedly inhibits the secretion, suggesting a possible function of a Gi-protein in the activation pathway. In order to determine the role of cAMP on GRF mediated secretion, mast cells were preincubated with isobutylmethylxanthine (IBMX) or cholera toxin, since both drugs greatly and enhance cAMP…

  40. 73.

    Robberecht P, De Neef P, Waelbroeck M, Camus JC, et al. · Pancreas · 1988 · PMID 3186683

    Crude membranes (27,000 g pellets) from five normal human pancreases were prepared. In the presence of GTP, the peptides of the secretin family stimulated adenylate cyclase activity, their order of potency being: secretin greater than helodermin greater than peptide histidine isoleucinamide (PHI) greater than or equal to vasoactive intestinal peptide (VIP) greater than growth hormone releasing factor (GRF) (1-29)-NH2. In addition, helodermin and PHI were more efficient than secretin. Secretin (3…

  41. 74.

    Coxam V, Davicco MJ, Opmeer FA, Ravault JP, et al. · Reproduction, nutrition, developpement · 1987 · PMID 3114840

    Plasma somatotropin (GH) and somatomedin C (IGF1) concentrations were measured by radioimmunoassay in 3-dy old and 10-day old calves intravenously injected with growth hormone releasing factor (GRF) 1-44, GRF 1-29 or thyrotropin-releasing hormone (TRH). In 3 day old animals the increase in plasma GH concentration was GRF 1-44 dose-related (50, 100, 200 pmoles . kg(-1) of body wt). In four 10-day old calves injected with the lowest dose, the increase in plasma GH concentration was not different f…

  42. 75.

    Bongers J, Offord RE, Felix AM, Lambros T, et al. · Biomedica biochimica acta · 1991 · PMID 1820039

    Enzymatic semisyntheses of growth hormone releasing factor (GRF), a 44-residue peptide amide hormone, from C-terminal acid precursors, are compared. A recombinant alpha-amidating enzyme was used to convert the glycine-extended precursor, GRF(1-44)-Gly-OH, to GRF(1-44)-NH2 in an essentially quantitative fashion. Trypsin was used to convert the precursors, GRF(1-43)-OH and GRF(1-44)-OH, to GRF(1-44)-NH2 (60 and 15% conversion, respectively) in a 75% v:v N,N'-dimethylacetamide solution containing a…

  43. 76.

    Hernández M, Fragoso J, Barrio R, Argente J, et al. · Hormone research · 1988 · PMID 2907992

    In the present study we report the effects of therapy with growth hormone-releasing factor (1-29)NH2 (GRF) on growth rate, plasma levels of insulin growth factor I (IGF-I) and growth hormone (GH) secretion in 11 children who were selected solely on the basis of their short stature and normal GH secretion on standard provocative tests. All children received GRF for 6 months (5 micrograms/kg body weight subcutaneously) each evening. The 24-hour GH secretory profile was studied before and after 6 m…

  44. 77.

    Pont L, Alechaga É, Terrero A, Monfort N, et al. · Journal of chromatography. A · 2020 · PMID 32971474

    Growth hormone-releasing hormone and its analogues sermorelin, tesamorelin and CJC-1295 are included in the prohibited list of the World Antidoping Agency. These target peptides are found at very low concentrations in urine (at the pg/mL level). For this reason, hyphenated enrichment and purification steps prior to mass spectrometric detection are required. Among different strategies, immunopurification based on magnetic beads is an excellent alternative, as it offers improved selectivity when t…

  45. 78.

    Farmer C, Petitclerc D, Pelletier G, Brazeau P · Journal of animal science · 1992 · PMID 1399876

    Fifty-two Yorkshire x Landrace gilts were equally allotted to four treatments: 1) controls, saline injections (CTL); 2) injections of 12 mg of growth hormone-releasing factor (GRF) (1-29)NH2 thrice daily (0700, 1500, and 2300) from d 100 of gestation until parturition (GEST); 3) injections of GRF thrice daily from d 3 to 29 of lactation (LACT); and 4) injections of GRF thrice daily during gestation (d 100 to parturition) and lactation (d 3 to 29) (GEST-LACT). Within 48 h of birth, litters were s…

  46. 79.

    Fournier A, Wang CT, Felix AM · International journal of peptide and protein research · 1988 · PMID 2896637

    The BOP reagent [benzotriazol-l-yl-oxy-tris-(dimethylamino)phosphonium hexa-fluorophosphate] introduced by Castro et al. [Tetrahedron Lett. (1975) 14, 1219-1222] is ideally suited for solid phase peptide synthesis. The rate of coupling using BOP compared favorably to DCC and other methods of activation including the symmetrical anhydride and DCC/HOBt procedures. BOP couplings using the solid phase procedure proceeded more rapidly and to a greater degree of completion for peptide bond formations…

  47. 80.

    Ko FY, Chen WP, Lin CY · Zhonghua Minguo xiao er ke yi xue hui za zhi [Journal]. Zhonghua Minguo xiao er ke yi xue hui · 1992 · PMID 1296432

    In an attempt to establish the reference pattern and the plasma growth hormone (GH) response to growth hormone releasing factor (GRF) (1-29)NH2, 5 normal stature with single kidney children and 14 with idiopathic GH deficient dwarfism received intravenous injections of 1 microgram/kg GRF(1-29)NH2. Plasma GH levels were measured at 0, 15, 30, 45, 60, 90, and 120 min after injection. The results showed that, first, in normal stature with single kidney children, each plasma GH reached peak level (8…

  48. 81.

    Robberecht P, Waelbroeck M, Coy D, De Neef P, et al. · Peptides · 1986 · PMID 3018703

    The ability of 30 synthetic GRF(1-29)-NH2 analogs to stimulate adenylate cyclase activity was investigated in membranes from rat adenopituitary, rat liver and rat pancreas. In adenopituitary membranes, GRF and GRF analogs interacted with specific GRF receptors, whereas in liver and pancreatic membranes, they interacted with VIP receptors. The C-terminal moiety of GRF was responsible for GRF receptor recognition as the hybrid analog (His1, D-Ala2)-GRF(1-9), VIP(10-28) stimulated pituitary adenyla…

  49. 82.

    Coy DH, Murphy WA, Lance VA, Heiman ML · Journal of medicinal chemistry · 1987 · PMID 3100799

    The excellent retention of biological potencies observed with human growth hormone releasing factor analogues with chains 29-44 amino acid residues long is suddenly lost when further amino acid residues are removed from the C-terminus. For instance, 1-27 and 1-24 exhibited little biological activity (greater than 1%) in vivo and in vitro in the rat. Studies were made to determine whether this was due to conformational changes rather than simply the loss of amino acids needed for direct receptor…

  50. 83.

    Wu D, Chen C, Zhang J, Bowers CY, et al. · The Journal of endocrinology · 1996 · PMID 8699133

    The mechanism of action of GH-releasing peptide-6 (GHRP-6) and GHRP-2 on GH release was investigated in ovine and rat pituitary cells in vitro. In partially purified sheep somatotrophs, GHRP-2 and GH-releasing factor (GRF) increased intracellular cyclic AMP (cAMP) concentrations and caused GH release in a dose-dependent manner; GHRP-6 did not increase cAMP levels. An additive effect of maximal doses of GRF and GHRP-2 was observed in both cAMP and GH levels whereas combined GHRP-6 and GHRP-2 at m…

  51. 84.

    Simpson RB, Armstrong JD, Harvey RW · Journal of animal science · 1992 · PMID 1526917

    Forty-one primiparous beef heifers were used over 2 yr to evaluate the effect of prepartum administration of a growth hormone-releasing factor analog (GRF-A) or growth hormone-releasing factor (GRF(1-29)-NH2) on somatotropin (ST), insulin-like growth factor I (IGF-I), milk production, heifer BW, and postpartum (PP) return to ovarian activity. Beginning on d -11 +/- 1 from parturition, heifers were administered (s.c.) GRF-A ([desNH2-Tyr1,D-Ala2,Ala15]GRF(1-29)-NH2, 2.5 micrograms/kg; Yr 1) or GRF…

  52. 85.

    Moore KL, Armstrong JD, Harvey RW, Campbell RM, et al. · Domestic animal endocrinology · 1992 · PMID 1617958

    Two experiments were conducted to determine the effects of immunoneutralization of growth hormone-releasing factor [GRF(1-29)-NH2] on concentrations of somatotropin (ST) and insulin-like growth factor I (IGF-I) in lactating beef cows. In Experiment 1, multiparous Hereford cows were immunized against 2 mg GRF(1-29)-(Gly)4-Cys-NH2 conjugated to human serum albumin (GRFi, n = 3) or 2 mg human serum albumin (HSAi, n = 3) at 52 +/- 1 d prior to parturition. Boosters (1 mg) were administered on days 1…

  53. 86.

    Simpson RB, Armstrong JD, Harvey RW, Miller DC, et al. · Journal of animal science · 1991 · PMID 1808188

    Angus and Charolais heifers (195 +/- 7 kg) were actively immunized against growth hormone-releasing factor (GRF) to evaluate the effect on concentrations of somatotropin (ST), insulin-like growth factor I (IGF-I), insulin (INS), growth, and onset of puberty. Primary immunizations were given at 184 +/- 7 d of age (d 0 of experiment) by injecting (s.c.) 1.5 mg of GRF-(1-29)-Gly-Gly-Cys-NH2 conjugated to 1.5 mg of human serum albumin (GRFi, n = 22) or 1.5 mg of human serum albumin (HSAi, n = 21). B…

  54. 87.

    Spicer LJ, Langhout DJ, Alpizar E, Williams SK, et al. · Molecular and cellular endocrinology · 1992 · PMID 1551471

    Recent studies have suggested that growth hormone-releasing factor (GRF), like vasoactive intestinal peptide (VIP), may enhance follicle-stimulating hormone (FSH)-stimulated steroidogenesis in cultured rat granulosa cells (GC). Because effects of GRF or VIP on GC proliferation have not been reported, we evaluated and compared the effect of GRF to that of VIP using cultured bovine GC. Undifferentiated GC from 1-5 mm bovine follicles were established for 2 days in medium containing 10% fetal calf…

  55. 88.

    Cacabelos R, Albarrán M, Diéguez C, Fariñas F, et al. · Methods and findings in experimental and clinical pharmacology · 1990 · PMID 2107369

    Attention-deficit hyperactivity disorder (ADHD) is a type of disruptive behavior of unknown etiology with a prevalence of 2.5-5% in school-age children. The useful evaluation of the GRF-induced GH response as a marker in some mental disorders led us to study the response of GH to the exogenous administration of GRF (1-29) NH2 (150 micrograms, i.v.) in ADHD children (N = 12, age = 7.78 +/- 1.66 years) and healthy children (N = 6; age = 8.73 +/- 2.24 years) in order to evaluate the functioning of…

  56. 89.

    Garcia JM, Swerdloff R, Wang C, Kyle M, et al. · The Journal of clinical endocrinology and metabolism · 2013 · PMID 23559086

    In the absence of panhypopituitarism and low serum IGF-I levels, the diagnosis of adult GH deficiency (AGHD) requires confirmation with a GH stimulation test. Macimorelin is a novel, orally active ghrelin mimetic that stimulates GH secretion. The objective of the study was to determine the diagnostic efficacy and safety of macimorelin in AGHD. This was a multicenter open-label study comparing the diagnostic accuracy of oral macimorelin with that of arginine+GHRH in AGHD patients and healthy, mat…

  57. 90.

    Cheng K, Chan WW, Barreto A, Convey EM, et al. · Endocrinology · 1989 · PMID 2541999

    His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 (GHRP-6) stimulated GH release from rat primary pituitary cells in a time- and dose-dependent manner. Stimulation was observed after a 15-min, but not a 4-h, incubation. The concentrations of GHRP-6 required for half-maximal and maximal stimulation were 7 x 10(-9) and 10(-7) M, respectively. GH release induced by GHRP-6 was not affected by the addition of either naloxone or the GRF antagonist [N-Ac-Tyr1,D-Arg2]GRF-(1-29)-NH2. The latter inhibited GRF-stimulated GH…

  58. 91.

    Boulanger L, Roughly P, Gaudreau P · Peptides · 1992 · PMID 1437711

    Clinical and veterinary uses of growth hormone-releasing factor [GRF(1- 29)NH2] require the design of analogs that are resistant to proteolysis by serum and liver degrading enzymes. This study investigated rat GRF(1-29)NH2 processing in serum and liver homogenate by means of high pressure liquid chromatography (HPLC). Synthetic rGRF(1-29)NH2 (30 microM) was incubated (0-120 min, 37 degrees C) in serum (49 +/- 8 mg prot./ml). The rGRF(1-29)NH2 (10 microM) was also incubated (0-120 min, 37 degrees…

  59. 92.

    Robberecht P, Coy DH, De Neef P, Camus JC, et al. · Neuroendocrinology · 1986 · PMID 3024053

    (125I-His1, D-Ala2, Nleu27)-growth hormone-releasing factor (GRF) (1-29)-NH2, initially developed as a possible radioligand for identifying GRF receptors in the anterior pituitary, was found to bind to rat hepatic membranes. The tracer was stable, bound rapidly and reversibly, and its dissociation was accelerated by GTP. Radioligand binding was enhanced by the divalent cations Mg2+, Ca2+ and Mn2+ and inhibited by the chelating agent EDTA. Vasoactive intestinal peptide (VIP), PHI, secretin, GRF(1…

  60. 93.

    Bongers J, Felix AM, Campbell RM, Lee Y, et al. · Peptide research · 1992 · PMID 1421807

    Recombinant alpha-amidating enzyme was used in the semisynthesis (1-5 mg scale) of human growth hormone-releasing factor, GRF(1-44)-NH2, by in vitro enzymatic oxidation of the glycine-extended precursor, GRF(1-44)-Gly-OH, prepared by solid-phase synthesis. The equipotent analog, GRF(1-29)-NH2, and the superactive analog, [Ala15]-GRF(1-29)-NH2, were also prepared by this route and were fully characterized. Isolated yields of about 75% were obtained, and the products each possessed full potency in…

  61. 94.

    Carlsson LM, Clark RG, Robinson IC · The Journal of endocrinology · 1990 · PMID 2116494

    Growth hormone inhibits its own secretion in animals and man but the mechanism for this inhibition is unclear: both stimulation of somatostatin release and inhibition of GH-releasing factor (GRF) release have been implicated. We have now studied the GRF responsiveness of conscious male and female rats under conditions of GH feedback induced by constant infusion of exogenous human GH (hGH). Intravenous infusions of hGH (60 micrograms/h) were maintained for 3 to 6 h whilst serial injections of GRF…

  62. 95.

    Dubreuil P, Brazeau P, Moreau S, Farmer C, et al. · Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2001 · PMID 11735232

    In 1982, Guillemin et al reported the isolation of the human (h) growth hormone (GH) releasing factor (GRF) from a pancreatic tumour in an acromegalic patient. Since then, work to develop potent GRF analogues has been widespread and the rat has been the main animal model used. The aim of the present study was to compare the efficacy, potency and specificity of two GRF analogues with those of the native GRF(1-29)NH(2)using pig (p) as the animal model. Two analogues, Al ([His(1), D-Ala(2), Ala(8,9…

  63. 96.

    Swanchara KW, Armstrong JD, Britt JH · Journal of animal science · 1999 · PMID 10438028

    Hormones within the somatotropin cascade influence several physiological traits, including growth and reproduction. Active immunization against growth hormone-releasing factor (GRFi) initiated at 3 or 6 mo of age decreased weight gain, increased deposition of fat, and delayed puberty in heifers. Two experiments were conducted to investigate the effects of GRFi on puberty and subsequent ovulation rate in gilts. Crossbred gilts were actively immunized against GRF-(1-29)-(Gly)2-Cys-NH2 conjugated t…

  64. 97.

    Hümmelink R, Rohwedder R, Sippell WG · Acta paediatrica Scandinavica. Supplement · 1987 · PMID 2886000

    The growth promoting potential of GRF(1-29)NH2 was studied in nine boys with short stature over three periods of 3 months. Their short stature was due to partial hGH deficiency/hGH neurosecretory dysfunction and was diagnosed by arginine and insulin stimulation tests and hGH nocturnal profiles. Four patients (Group I) were given GRF, 3-4 micrograms/kg s.c. b.d. during the first period of 3 months, and after an interval of 1 month, the same dose once daily during the second treatment period of 3…

  65. 98.

    Pastoureau P, Charrier J, Blanchard MM, Boivin G, et al. · Domestic animal endocrinology · 1989 · PMID 2515938

    The effects of a long term treatment with human GRF(1-29)NH2 on plasma growth hormone (GH), somatomedin C (Sm-C), histomorphometric parameters of bone growth and body composition were investigated in normal and low birthweight male lambs. The animals were divided into two groups according to their birthweight: 24 normal birthweight (NBW) lambs weighing more than 4 kg and 22 low birthweight (LBW) lambs weighing less than 2.5 kg at birth. Half of the animals in each group received two daily subcut…

  66. 99.

    Lodén M, Faijerson Y · Acta pharmaceutica Suecica · 1988 · PMID 2901184

  67. 100.

    Barenton B, Duclos M, Diaz J, Deletang F, et al. · Reproduction, nutrition, developpement · 1987 · PMID 3114837

    Human growth hormone releasing hormone (GRF 1-44 or GRF 1-29) was administered to lambs at two different physiological stages (suckling: 5-6 week-old and weaned: 14-15 week-old) when growth hormone (GH) secretory patterns were different: suckling lambs exhibited flat basal GH profiles (5-10 ng/ml) while the weaned lambs had frequent spontaneous episodes of GH release (15-65 ng/ml). The iv injection of GRF evoked an immediate release of GH. In each case, plasma GH levels reached a maximum 1-4 min…

  68. 101.

    Spicer LJ, Enright WJ · Journal of animal science · 1991 · PMID 1905710

    To determine whether long-term administration of growth hormone (GH)-releasing factor (GRF) and(or) thyrotropin-releasing hormone (TRH) alters ovarian follicular fluid (FFL) concentrations of insulin-like growth factor-I (IGF-I), progesterone, and estradiol (E2), and follicular growth, Friesian x Hereford heifers (n = 47; 346 +/- 3 kg) were divided into the following four groups: control (vehicle; n = 11); 1 micrograms GRF (human [Des NH2 Tyr1, D-Ala2, Ala15] GRF [1-29]-NH2).kg-1 BW.d-1 (n = 12)…

  69. 102.

    Harvey RW, Armstrong JD, Heimer EP, Campbell RM · Journal of animal science · 1993 · PMID 8270507

    Large-framed Simmental and Charolais steers were actively immunized against growth hormone-releasing factor (GRF) to evaluate the effect on growth, carcass characteristics (especially intramuscular fat deposition), and concentrations of somatotropin (ST) and IGF-I. Primary immunizations of 1.5 mg of GRF-(1-29)-Gly-Gly-Cys-NH2 conjugated to 1.5 mg of human serum albumin (GRFi, n = 12) or 1.5 mg of human serum albumin (HSAi, n = 12) were given at approximately 10 mo of age. Booster immunizations o…

  70. 103.

    Su CM, Jensen LR, Heimer EP, Felix AM, et al. · Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 1991 · PMID 1826667

    The stability of growth-hormone releasing factor (growth regulating factor; GRF) analogs in porcine plasma was examined. GRF analogs were incubated in porcine plasma at 37 degrees C, extracted and subsequently analyzed using high performance liquid chromatography (HPLC). GRF(1-29)-NH2 was rapidly broken down in the plasma with a degradation rate of t1/2 = 13 min. The primary degradation product was identified as GRF(3-29)-NH2. Substitution of Gly15 by Ala15 slightly prolonged the plasma half-lif…

  71. 104.

    Xie ZQ, Hirose T, Hakoda H, Ito Y · British journal of pharmacology · 1991 · PMID 1667294

    1. The effects of vasoactive intestinal polypeptide (VIP) antagonists [AC-Tyr1, D-Phe2]-GRF(1-29)-NH2 and [4-Cl-D-Phe6, Leu17]-VIP on excitatory neuroeffector transmission in the dog and cat trachea were investigated by use of microelectrode, double sucrose-gap and tension recording methods. 2. In the dog trachea, repetitive stimuli at high frequency (20 Hz) markedly enhanced the amplitude of contraction, the amplitude of contractions evoked by 50 stimuli at 20 Hz relative to that evoked by 5 st…

  72. 105.

    Wu D, Chen C, Zhang J, Katoh K, et al. · Journal of neuroendocrinology · 1994 · PMID 8049717

    Continuous perifusion of pituitary cells was used to study the effects of a newly synthesized GHRP (GHRP-1 or KP 101) on growth hormone (GH) secretion from ovine pituitary cells and these have been compared to effects of growth hormone-releasing factor (GRF) and the original growth hormone-releasing peptide (GHRP-6). GH was continuously released at a constant rate during perifusion and secretion was increased by KP 101, GHRP-6 and GRF in a dose-dependent manner. The half-maximal effective dose o…

  73. 106.

    Bongers J, Lambros T, Liu W, Ahmad M, et al. · Journal of medicinal chemistry · 1992 · PMID 1433202

    A superpotent analog of human growth hormone-releasing factor, [desNH2Tyr1,D-Ala2,Ala15]-GRF(1-29)-NH2 (4), was prepared from the precursor, [Ala15,29]-GRF(4-29)-OH (1), by a two-step enzymatic semisynthesis. The amidated C-terminus, essential for high biological potency, was obtained via a carboxypeptidase Y-catalyzed exchange of Ala29-OH for Arg29-NH2 to produce [Ala15]-GRF(4-29)-NH2 (2). The N-terminal desNH2Tyr-D-Ala moiety, which greatly increases in vivo duration of action, was then incorp…

  74. 107.

    Blanchard MM, Goodyer CG, Charrier J, Kann G, et al. · The American journal of physiology · 1991 · PMID 1673320

    To examine the effects of anabolic agents given during late gestation on the maternal and fetal somatotropic axes, we injected pregnant ewes twice daily with 0.15 mg somatocrinin (GRF)-(1-29) for 10 days beginning on day 130 of gestation. Maternal and fetal endocrine changes were compared with control animals using both in vivo and in vitro approaches. Treatment with GRF increased maternal plasma levels of growth hormone (GH) and insulin-like growth factor I (IGF-I;P less than 0.05) but not IGF-…

  75. 108.

    Timms M, Ganio K, Forbes G, Bailey S, et al. · Drug testing and analysis · 2019 · PMID 30489688

    CJC-1295 is a 30 amino acid peptide-based drug that stimulates the release of growth hormone (GH) from the pituitary gland. It is unique among performance-enhancing peptides due to the presence of a reactive maleimidopropionic acid group that covalently links the peptide to free thiols on the surface of plasma proteins. Once conjugated, CJC-1295 remains active in the bloodstream for significantly longer than non-conjugated peptide-based drugs that are rapidly excreted. Conjugation of CJC-1295 to…

  76. 109.

    Lumpkin MD, Mulroney SE, Haramati A · Endocrinology · 1989 · PMID 2492921

    We previously reported that systemic administration of the recently described GRF peptide antagonist (N-Ac-Tyr1,D-Arg2)GRF-(1-29)-NH2 to adult male rats would suppress the pulsatile release of GH. In the present study, we have sought to determine whether this same antagonist would be efficacious in immature male rats to block spontaneous GH secretion and, as a result, retard several parameters of somatic growth. Indwelling Silastic catheters were placed into the jugular veins of immature male ra…

  77. 110.

    Abribat T, Lapierre H, Dubreuil P, Pelletier G, et al. · Domestic animal endocrinology · 1990 · PMID 2107053

    Plasma insulin-like growth factor-I (IGF-I) concentrations were monitored in Holstein females through different periods of their growth, lactation and after acute or chronic growth hormone-releasing factor (GRF) administration. Plasma samples were radioimmunoassayed using a human IGF-I antibody after a 24 hr incubation in a HCl(.1N)-glycine(.2M) buffer (pH 2). In a first study, IGF-I concentrations were measured in Holstein females of different ages and(or) stages of lactation (n = 6 per group).…

  78. 111.

    Arsenijevic Y, Rivest RW, Eshkol A, Sizonenko PC, et al. · Endocrinology · 1987 · PMID 2888646

    The ability of human (h)GRF-(1-29)NH2 to stimulate GH secretion was studied in cannulated adult rats. In order to suppress endogenous GRF secretion and the inhibitory action of hypothalamic somatostatin (SRIF), rats were anesthetized with sodium pentobarbital. Intravenous administration of hGRF-(1-29)NH2 elicited a dose-dependent response of plasma GH, with 250 ng/kg being the smallest effective dose in male rats. In female rats, for each dose tested (250 to 70,000 ng/kg), the GH response repres…

  79. 112.

    Hocart SJ, Murphy WA, Coy DH · Journal of medicinal chemistry · 1990 · PMID 2141879

    Previous peptide structure-activity investigations employing the psi[CH2NH] peptide bond isostere have produced antagonists when inserted into various sequences. These include bombesin, in which the incorporation of Leu13 psi[CH2NH]Leu14 produced a potent antagonist, and tetragastrin, with which Boc-Trp-Leu psi[CH2NH]Asp-Phe-NH2 is an antagonist. In this study, we chose to investigate the effect of this isostere on growth hormone-releasing factor (1-29) amide. Analogues were prepared by solid-ph…

  80. 113.

    Wu D, Chen C, Katoh K, Zhang J, et al. · The Journal of endocrinology · 1994 · PMID 8169551

    A newly synthesised GH-releasing peptide, KP 102 (also named GHRP-2), was studied in an in vitro perifusion system of primary cultured ovine anterior pituitary cells. Application of KP 102 to the perifusion medium caused a dose-dependent increase in GH secretion. Dose-response relationships indicated that KP 102 had similar potency to GRF and was 10-fold more potent than earlier generations of GH-releasing peptide (GHRP-6 and GHRP-1) tested in same system. The response to a second application of…

  81. 114.

    Coy DH, Murphy WA, Lance VA, Heiman ML · Peptides · 1986 · PMID 3092197

    Previous research on the favorable effects of mild conformational restriction in the N-terminal region of glucagon has led us to carry out analogue studies on the sequence-related 1-12 region of GRF(1-29)NH2. Replacement of each of the first 11 amino acids by its D-isomer in turn gave a total of 5 analogues exhibiting increases in potency. Other analogues containing multiple D-amino acid replacements were also examined and found to be highly potent, for instance: D-Tyr-1,D-Ala-2, 2630; His-1,D-A…

  82. 115.

    Farmer C, Gaudreau P · Biology of the neonate · 1997 · PMID 9428996

    The present study was conducted to establish whether growth hormone (GH) releasing factor (GRF) is present in porcine placenta. Various concentrations of placental extracts from sows at 90 and 110 days of gestation were added to porcine anterior pituitary cells in culture. The extract-induced GH secretion was compared to that of GRF(1-29)NH2. Experiments were also performed in the presence of the GRF receptor antagonist N alpha-acetyl(D-Arg2-Ala15) rat GRF(1-29)NH2 (10(-7) M). Significant effect…

  83. 116.

    Kumar S, Char H, Patel S, Piemontese D, et al. · Journal of pharmaceutical sciences · 1992 · PMID 1403695

    The shortened analogue of growth hormone releasing factor (GRF) Ro 23-7861 (1) has a molecular weight of 3929 daltons [equivalent to GRF (1-29)] and is more potent than the endogenous GRF (1-44). The in vitro hairless guinea pig model and vertical and horizontal diffusion cell assemblies were used to study the effect of iontophoresis on the permeability to skin of 1. The transport of 1 across the skin was studied by monitoring the rate of its appearance in the receiver compartment with a radioim…

  84. 117.

    Painson JC, Tannenbaum GS · Endocrinology · 1991 · PMID 1674685

    A striking sexual dimorphism exists in the pattern of GH secretion and rate of somatic growth; however, the mechanism(s) mediating this sex difference is unknown. To elucidate the physiological roles of the hypothalamic neuropeptides, somatostatin (SRIF) and GRF, and their interrelation, in generating the sexually dimorphic GH secretory pattern we examined: 1) GH responsiveness to exogenous GRF and 2) the effects of immunoneutralization of endogenous SRIF and GRF on GH secretory dynamics, in fre…

  85. 118.

    Luo DS, McKeown BA, Rivier J, Vale W · General and comparative endocrinology · 1990 · PMID 1981568

    To study the hypothalamic control of growth hormone (GH) release in lower vertebrates, we employed an in vitro technique using a monolayer cell culture system of rainbow trout pituitary glands. Two newly purified carp brain growth hormone-releasing factors, carp GRF(1-45) and carp GRF(1-29), and synthetic somatostatin-14 (SST-14) were applied to the cultured pituitary cells. The results indicate that: (1) The carp GRFs had a dose-related potency in stimulating growth hormone release. The dose of…

  86. 119.

    Plouzek CA, Vale W, Rivier J, Anderson LL, et al. · Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) · 1988 · PMID 3131776

    The effects of iv administration of growth hormone-releasing factor (GRF) on growth hormone (GH) release and on nitrogen metabolism were measured in prepubertal calves. Crossbred beef heifers (111 kg) were used in a Latin square design to test the effects of 0, 0.01, 0.033, 0.067, and 0.1 microgram human pancreatic (hp) GRF [hpGRF (1,40)OH]/kg body wt on plasma GH concentrations. When they were given doses of 0.067 and 0.1 microgram hpGRF/kg body wt, plasma GH increased (P less than 0.05) within…

  87. 120.

    Lengyel AM, Tannenbaum GS · Endocrinology · 1987 · PMID 2881773

    Calcitonin (CT) binds to specific receptors in the hypothalamus and has been localized in the pituitary, suggesting a potential neuroendocrine role for this peptide. We and others have previously shown that CT given centrally markedly suppresses pulsatile GH secretion. However, the mechanism mediating this response remains to be elucidated. In the present study, we assessed the involvement of the two hypothalamic GH-regulatory peptides, somatostatin (SRIF) and GH-releasing factor (GRF), using a…

  88. 121.

    Youn YS, Na DH, Yoo SD, Song SC, et al. · Journal of chromatography. A · 2004 · PMID 15633743

    A one-step chromatographic method capable of separating all isomers of polyethylene glycol (PEG)-growth hormone-releasing factor (GRF) (1-29) conjugates was developed. The unmodified GRF (1-29) and seven different isomers of PEG-GRF (1-29) conjugates were separated by using a simple reversed-phase HPLC method depending on the differences of hydrophobicity due to the number and site of PEG attachment. The PEGylation sites of all isomers of PEG-GRF (1-29) conjugates were identified by determining…

  89. 122.

    Tannenbaum GS, Lapointe M, Gurd W, Finkelstein JA · Endocrinology · 1990 · PMID 1979030

    GH secretion is markedly blunted in obesity; however, the mechanism(s) mediating this response remains to be elucidated. In the present study we examined the involvement of the two hypothalamic GH-regulatory hormones, GH-releasing factor (GRF) and somatostatin (SRIF), using the genetically obese male Zucker rat. Spontaneous GH, insulin, and glucose secretory profiles obtained from free moving, chronically cannulated rats revealed a marked suppression in amplitude and duration of GH pulses in obe…

  90. 123.

    Dubreuil P, Pelletier G, Petitclerc D, Lapierre H, et al. · Endocrinology · 1989 · PMID 2569391

    Three experiments were conducted with growing pigs actively immunized against a protein-conjugated somatostatin (SRIF) in Freund's adjuvant. In the first experiment, blood from 24-week-old pigs (seven immunized and eight control) was sampled at 20-min intervals for 6 h to evaluate basal GH concentrations. The animals were then injected iv with porcine GH-releasing factor (GRF)-(1-29)NH2 (10 micrograms/kg). Before GRF stimulation, immunized animals had higher (P less than 0.05) baseline mean GH l…

  91. 124.

    Xu XJ, Wiesenfeld-Hallin Z · Neuropeptides · 1991 · PMID 2067598

    The effect of intrathecal (i.t.) vasoactive intestinal peptide (VIP) and an analogue of growth hormone releasing factor (GRF) with putative VIP antagonistic property, (Ac-Try1, D-Phe2)-GRF-(1-29), on the nociceptive flexor reflex was studied in decerebrate, spinalized, unanesthetized rats. VIP (10 pM) facilitated the flexor reflex for several minutes. A similar facilitation was induced by the VIP antagonist applied i.t. with a potency 15 times less than that of VIP. Pre-administration of the VIP…

  92. 125.

    Theriault Y, Boulanger Y, Saunders JK · Biopolymers · 1988 · PMID 3149201

  93. 126.

    Armstrong JD, Esbenshade KL, Johnson JL, Coffey MT, et al. · Journal of animal science · 1990 · PMID 2107160

    Cyclic gilts (96 +/- 1 kg) were used to determine the effect of active immunization against growth hormone-releasing factor GRF(1-29)-NH2 on concentrations of growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Gilts were immunized against GRF conjugated to human serum albumin (GRF-HSA, n = 5) or HSA alone at 180 d of age (wk 0). Booster doses were administered at wk 9 and 13. Seven days after the second booster (wk 14), blood samples were collected at 15-min intervals for 6 h before f…

  94. 127.

    Bongers J, Liu W, Lambros T, Breddam K, et al. · International journal of peptide and protein research · 1994 · PMID 7982755

    We recently described a two-step enzymatic semisynthesis of the superpotent analog of human growth hormone releasing factor, [desNH2Tyr1,D-Ala2,Ala15]-GRF(1-29)-NH2 (4), from the precursor, [Ala15,29]-GRF(4-29)-OH (1). C-Terminal amidation of 1 to form [Ala15]-GRF(4-29)-NH2 (2) was achieved by carboxypeptidase-Y-catalyzed exchange of Ala29-OH for Arg-NH2. The target analog 4 was then obtained by acylation of segment 2 with desNH2Tyr-D-Ala-Asp(OH)-OR (3) (R = CH3CH2- or 4-NO2C6H4CH2-) catalyzed b…

  95. 128.

    Glavaski-Joksimovic A, Jeftinija K, Jeremic A, Anderson LL, et al. · The Journal of endocrinology · 2002 · PMID 12475374

    The effects of a GH secretagogue, L-692,585 (L-585), and human GH-releasing hormone (hGHRH) on calcium transient and GH release were investigated in isolated porcine pituitary cells using calcium imaging and the reverse hemolytic plaque assay (RHPA). Somatotropes were functionally identified by the application of hGHRH. All cells that responded to hGHRH responded to L-585 application. Perfusion application of 10 microM hGHRH and L-585 for 2 min resulted in an increase in intracellular calcium co…

  96. 129.

    Ranke MB, Blum WF, Haug F, Rosendahl W, et al. · Acta endocrinologica · 1987 · PMID 3687318

    In a total of 56 children and adolescents with Turner's syndrome (41 with karyotype 45,X) basal serum levels of somatomedin bioactivity, Sm-C/IGF-I (RIA), IGF II (RIA), GH response to arginine and GHRH (GRF(1-29)NH2), and spontaneous GH secretion during 5.5 h of deep sleep were determined in a cross-sectional manner. GH responses to GRF and arginine as well as IGF-II levels were found to be in the normal range. Levels of somatomedin bioactivity were higher than normal before a bone age of 10 yea…

  97. 130.

    Michalkiewicz M, Huffman LJ, Hedge GA · Peptides · 1991 · PMID 1815206

    We used three putative vasoactive intestinal peptide (VIP) antagonists: 1) [4C1-D-Phe6,Leu17]VIP, 2) [N-Ac-Tyr1,D-Phe2] GRF(1-29)-NH2, and 3) VIP(10-28) to assess the involvement of endogenous VIP in the regulation of thyroid hormone secretion and thyroid blood flow (BF). We measured thyroid BF in ketamine-pentobarbital-anesthetized rats using the microsphere technique. Increases in thyroid BF induced by VIP administration (30 pmol-1.5 nmol/100 g b.wt.) were not affected by any of the three comp…

  98. 131.

    Estévez MD, Botana MA, Arnáez E, Vieytes MR, et al. · International archives of allergy and immunology · 1993 · PMID 7679022

    We have studied the release of histamine elicited by human GRF(1-29)NH2 on rat peritoneal and pleural mast cells. The secretion is temperature dependent, the release being optimal at 37 degrees C, and it can be inhibited with antimycin A. The activation of pleural and peritoneal mast cells is similar, but there is a slight inhibition for both populations after purification with Percoll.

  99. 132.

    Breddam K, Widmer F, Meldal M · International journal of peptide and protein research · 1991 · PMID 2019477

    The applicability of serine carboxypeptidase catalysed transpeptidation reactions, using amino acid amides as nucleophiles, for C-terminal amidation of peptides has been investigated. With the aim of converting an unamidated precursor into GRF(1-29)-NH2, an interesting biologically active derivative of growth hormone releasing factor, a number of model reactions were initially investigated. In such a transpeptidation reaction, where the C-terminal amino acid is replaced by the amino acid amide,…

  100. 133.

    Enright WJ, Prendiville DJ, Spicer LJ, Stricker PR, et al. · Journal of animal science · 1993 · PMID 8407651

    The objective of this study was to determine the effect of long-term administration of a growth hormone (GH)-releasing factor analog (GRFa) and(or) thyrotropin-releasing hormone (TRH) on growth, feed efficiency, carcass characteristics, and blood hormones and metabolites in beef heifers. Crossbred heifers (n = 48; 345.9 +/- 2.8 kg) were divided into four equal groups: control (vehicle), 1 microgram of GRFa (human GRF 1-29 analog).kg BW-1.d-1, 1 microgram of TRH.kg BW-1.d-1, or GRFa + TRH. Daily…

  101. 134.

    Lanzi R, Tannenbaum GS · Endocrinology · 1992 · PMID 1347739

    Exogenous GH is known to exert a negative feedback effect on its own responsiveness to GH-releasing factor (GRF); however, the mechanism is not known. In the present study we examined the time course of effects of a single sc administration of recombinant human (rh) GH on GH responsiveness to GRF and investigated the possible involvement of somatostatin (SRIF) in this response. Free-moving adult male rats were administered 200 micrograms rhGH, sc, at 0800 h and subsequently challenged with 1 mic…

  102. 135.

    Farmer C, Dubreuil P, Pelletier G, Petitclerc D, et al. · Domestic animal endocrinology · 1991 · PMID 1684146

    The hormonal responses of gestating sows to immunization against somatostatin conjugated to bovine serum albumin (SRIF-IMM) and/or injections of growth hormone-releasing factor (GRF) were studied with thirty-eight second parity sows. Immunization against bovine serum albumin (BSA-IMM) was used as control. First immunizations were done on day 30 and boosters were given on days 44, 58, 72, 86 and 100 of gestation. Injections of GRF (9 mg of GRF (1-29)NH2 per injection) or saline were given at 0800…

  103. 136.

    Santos Español C, Acosta Delgado D, García-Luna P, Navarro González E, et al. · Revista clinica espanola · 1987 · PMID 2885902

  104. 137.

    Pastoureau P, Barenton B, Blanchard M, Boivin G, et al. · Reproduction, nutrition, developpement · 1988 · PMID 3131856

    Injections of hGRF rapidly stimulated GH secretion in lamb and this response was significantly higher in hypotrophic than in normal lambs. The treatment had an effect on body composition reducing the retention of lipids and the energy level and increasing calcium and phosphorus content. The results showed that GRF affected both metabolism and skeletal growth of ruminants, stimulating specially the production of Sm-C and proliferation of chondrocytes.

  105. 138.

    Bercu BB, Yang SW, Masuda R, Walker RF · Endocrinology · 1992 · PMID 1315249

    The purpose of this study was to evaluate the contribution of endogenous GH-releasing hormone (GHRH) to exogenous GH-releasing hexapeptide (GHRP-6) activity, and to determine whether TRH or GnRH are endogenous analogs of GHRP-6. The activity of GHRP-6, a synthetic GH secretagogue, was significantly attenuated in rats administered GHRH antiserum or alpha-methyl-rho-tyrosine to reduce endogenous GHRH concentrations, and also in rats administered 5-50 micrograms/kg of [N-Ac-Tyr1,D-Arg2]-GRF 1-29 am…

  106. 139.

    Ramos M, Fernández A, Ferrández A, Mayayo E, et al. · Anales espanoles de pediatria · 1987 · PMID 2892455

    A good response after an intravenous bolus of GRF-1-29 NH2 in patients with hypopituitary dwarfism localities the site of the GH-deficiency in the hypothalamus (GRF deficiency). These patients could be treated with GH and GRF. Never the less some patients with hypothalamic responses after TRH don't respond after GRF. Probably these non responders need GRF in pulsatile or prolonged administration and T4 substitution before and during the test if TSH is also deficient. At least some cases without…

  107. 140.

    Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Rick Hatch GF, Gamradt SC, Weber AE. · 2026 · PMID 41476424

    <h4>Background</h4>Therapeutic peptides are short-chain amino acids that regulate cellular functions and facilitate biochemical processes. In recent years, there has been significant growth in the global market for therapeutic peptides and thus its popularity among patients. Given the increase in the development of peptides and increased marketing to patients for orthopaedic injuries, it is critical for orthopaedic surgeons to understand the current evidence behind these therapeutic peptides.<h4…

  108. 141.

    Al Musaimi O. · 2024 · PMID 38540684

    Peptides continue to gain significance in the pharmaceutical arena. Since the unveiling of insulin in 1921, the Food and Drug Administration (FDA) has authorised around 100 peptides for various applications. Peptides, although initially derived from endogenous sources, have evolved beyond their natural origins, exhibiting favourable therapeutic effectiveness. Medicinal chemistry has played a pivotal role in synthesising valuable natural peptide analogues, providing synthetic alternatives with th…

  109. 142.

    Pedrolli F, Morello G, Gesmundo I, Banfi D, Ferro A, Wangpaichitr M, Sha W, Tamagno E, Schally AV, Guglielmotto M, Granata R. · 2026 · PMID 41946684

    Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by amyloid-β (Aβ) accumulation, tau hyperphosphorylation, neuroinflammation, and synaptic loss. Existing therapies provide only modest symptomatic relief and fail to slow disease progression. Beyond its role in promoting pituitary growth hormone (GH) secretion, growth hormone-releasing hormone (GHRH) has shown neuroprotective effects in experimental ischemic stroke and spinal muscular atrophy. Here, we explored th…

  110. 143.

    Rosenberg AE, Taylor B, Rasquinha RD, Khan H, Quinn M, Marcaccio S, Lemme N. · 2026 · PMID 41877514

  111. 144.

    Mavrych V, Shypilova I, Bolgova O. · 2026 · PMID 42021992

    <h4>Background</h4>Peptide therapeutics represent an emerging frontier in gerontological medicine, targeting fundamental hallmarks of aging including metabolic dysfunction, telomere attrition, tissue repair impairment, and hormonal decline.<h4>Objective</h4>To comprehensively review the mechanisms, clinical applications, evidence base, and safety profiles of therapeutic peptides with demonstrated or potential applications in healthy aging and age-related conditions.<h4>Methods</h4>A comprehensiv…

  112. 145.

    Barabutis N. · 2020 · PMID 32289177

    Growth hormone-releasing hormone is a hypothalamic neuropeptide, which regulates the secretion of growth hormone by the anterior pituitary gland. Recent evidence suggest that it exerts growth factor activities in a diverse variety of in vivo and in vitro experimental malignancies, which are counteracted by growth hormone-releasing hormone antagonists. Those peptides support lung endothelial barrier integrity by suppressing major inflammatory pathways and by inducing the endothelial defender P53.…

  113. 146.

    Dulce RA, Hatzistergos KE, Kanashiro-Takeuchi RM, Takeuchi LM, Balkan W, Hare JM. · 2025 · PMID 39883351

    Growth hormone (GH)-releasing hormone (GHRH), a hypothalamic peptide initially characterized for its role in GH regulation, has gained increasing attention due to its GH-independent action on peripheral physiology, including that of the cardiovascular system. While its effects on the peripheral vasculature are still under investigation, GHRH and synthetic agonists have exhibited remarkable receptor-mediated cardioprotective properties in preclinical models. GHRH and its analogs enhance myocardia…

Preprints (not yet peer-reviewed)

3
  1. 147.

    Mendias CL, Awan TM. · 2026

    Peptides are a rapidly expanding drug class with a parallel and largely unregulated gray market that sells preparations directly to consumers for self-administration. The use of gray market peptides has grown substantially, with patients self-administering these compounds for purported benefits including accelerated musculoskeletal injury recovery, muscle hypertrophy, fat loss, and athletic performance enhancement. The objective of this study was to evaluate the purity, measured abundance, and e…

  2. 148.

    Mendias CL, Awan TM. · 2026

    Peptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins. Their use in sports medicine is rapidly expanding, driven by patient demand for accelerated injury recovery and performance enhancement. While numerous peptide drugs have undergone a rigorous approval process that evaluates both safety and efficacy, a parallel "gray market" of unapproved compounds has emerged, operating largely outside regulatory oversight. Our objective…

  3. 149.

    Mendias CL, Awan TM. · 2025

    Peptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins. Their use in sports medicine is rapidly expanding, driven by patient demand for accelerated injury recovery and performance enhancement. While numerous peptide drugs have undergone a rigorous approval process that evaluates both safety and efficacy, a parallel "gray market" of unapproved compounds has emerged, operating largely outside regulatory oversight. Our objective…

Curated sources on file

6
  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
  6. 6.

Continue reading